metformin has been researched along with ARSA Deficiency in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metachromatic leukodystrophy is a neurological lysosomal deposit disease that affects public health despite its low incidence in the population." | 1.72 | A model of metformin mitochondrial metabolism in metachromatic leukodystrophy: first description of human Schwann cells transfected with CRISPR-Cas9. ( Bautista-Niño, PK; Sanchez-Álvarez, NT; Serrano-Díaz, NC; Trejos-Suárez, J, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sanchez-Álvarez, NT | 1 |
| Bautista-Niño, PK | 1 |
| Trejos-Suárez, J | 1 |
| Serrano-Díaz, NC | 1 |
1 other study available for metformin and ARSA Deficiency
| Article | Year |
|---|---|
A model of metformin mitochondrial metabolism in metachromatic leukodystrophy: first description of human Schwann cells transfected with CRISPR-Cas9.
Topics: CRISPR-Cas Systems; Humans; Leukodystrophy, Metachromatic; Metformin; Reactive Oxygen Species; Schwa | 2022 |